Last checked at 13 Nov 2008 07:00
13 November 2008
Phytopharm plc
Board Changes
GODMANCHESTER, Cambridgeshire, U.K.- The Board of Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces that the Company has received notice of termination of employment contract from Daryl Rees, Chief Executive Officer, and Piers Morgan, Chief Financial Officer. They cease to be Directors of the Company with immediate effect.
A further announcement in respect of the Company's future direction and management will be made in due course.
The Company's preliminary results will be announced on 27 November 2008 as planned.
-Ends-
Notes to Editors
Phytopharm plc
Phytopharm is a pharmaceutical development and functional food company. Our products are developed from medicinal plants, thereby reducing the development risk, cost and time to market. As a virtual company, Phytopharm's business model is centred on a lean cash burn with all laboratory, manufacturing and clinical work out-sourced to specialists, while core competencies such as strategy and management are maintained in-house. Close collaboration with charitable organisations enhances our interaction with worldwide specialists and accelerates our development programmes increasing their value.
| Enquiries Phytopharm plc Alistair Taylor, Chairman Sandy Morrison, Non-Executive Director +44 1480 437 697 | U.K. Investor Relations FD David Yates John Dineen +44 207 831 3113 |
For further information about Phytopharm please see our website at http://www.phytopharm.com